Vigophos 100 mg / ml + 0.05 mg / ml solution for injection for cattle, horses and dogs

Authorised

- Cyanocobalamin
- Butafosfan

Product identification

Medicine name:
Vigophos 100 mg / ml + 0.05 mg / ml solution for injection for cattle
Vigophos 100 mg / ml + 0.05 mg / ml solution for injection for cattle, horses and dogs

Active substance:
Cyanocobalamin

Butafosfan

Target species:
Cattle

Route of administration:
Intravenous use

Product details

Active substance and strength:
Cyanocobalamin
0.05 milligram(s) / 1.00 millilitre(s)

Butafosfan
100.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intravenous use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA12CX91

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Ireland

Available in:
Ireland

Package description:
Carton containing 12 Type II amber glass vials of 100 ml closed with a coated bromobutyl or chlorobutyl rubber stopper and sealed with an aluminium cap
Carton containing 6 Type II amber glass vial of 100 ml closed with a coated bromobutyl or chlorobutyl rubber stopper and sealed with an aluminium cap
Carton containing 1 Type II amber glass vial of 100 ml closed with a coated bromobutyl or chlorobutyl rubber stopper and sealed with an aluminium cap

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Industrial Veterinaria S.A.

Marketing authorisation date:
9/03/2018

Manufacturing sites for batch release:
aniMedica GmbH
Industrial Veterinaria S.A.
aniMedica Herstellungs GmbH

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10425/007/001

Date of authorisation status change:
9/03/2018

Reference member state:
Netherlands

Procedure number:
NL/V/0426/001

Concerned member states:
Austria Belgium Czechia Denmark Germany Hungary Ireland Italy Poland Portugal Romania Slovakia Slovenia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

PuAR updated.pdf
